Hanshow Wins the Technology Vendor of the Year at 2025 RTIH Innovation Awards in London
24.10.2025 06:00:00 EEST | Business Wire | Press release
Hanshow, a global leader in digital retail solutions, has been honoured at the 2025 Retail Technology Innovation Hub (RTIH) Innovation Awards, winning the Technology Vendor of the Year title for its pioneering shelf marketing solution. The recognition underscores Hanshow’s commitment to redefining how retailers and brands engage with shoppers through NFC-enabled ESLs that seamlessly connect physical stores with digital engagement.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251023122859/en/
The RTIH Innovation Awards are widely regarded as one of the most influential recognitions in the global retail technology sector. Each year, the awards celebrate organisations driving innovation, digital transformation, and operational excellence in a fast-moving omnichannel world. The 2025 ceremony, held at The HAC in central London, brought together senior retail executives, technology innovators, and thought leaders shaping the future of connected commerce.
This year’s awards introduced new categories such as Best Data Analytics-Driven Retail Initiative and Best Use of Automation in the Retail Sector, reflecting the industry’s accelerating focus on data intelligence, automation, and customer experience. According to RTIH, submissions were judged on “clear project objectives, innovative implementation, and demonstrable business results,” with entries welcomed from companies across the globe. The judging panel featured senior experts from major retail and technology organisations including Amazon Just Walk Out, Boots, Rohlik Group, and East of England Co-op, underscoring the credibility and global scope of the programme.
Hanshow’s award-winning Shelf Marketing Solution transforms traditional ESLs into interactive digital media touchpoints. Shoppers can simply tap their smartphones on an ESL to instantly access brand pages, promotional offers, or product information—no QR codes or app downloads required.
The solution enhances transparency, convenience, and engagement while enabling retailers and brands to measure campaign performance in real time. It has been successfully adopted by leading retailers such as Leroy Merlin in France and FairPrice Group in Singapore, where shoppers can simply tap their smartphones on an ESL to view detailed product information, empowering them to make more informed purchasing decisions.
At the same time, it enables retailers to deliver personalized, data-driven campaigns, while helping brandsincrease conversion rates and achieve higher ROI. By transforming store shelves into interactive digital touchpoints, the solution creates a new in-store retail media channelthat connects consumers, retailers, and brands, bridging the online and offline journey and unlocking measurable business value.
In one pilot across four retail stores in China, the solution achieved an impressive 24% coupon redemption rate, far exceeding the industry average of 1–9% for traditional in-store or app-based campaigns. The initiative further demonstrated the strong consumer engagement potential of Hanshow’s Shelf Marketing Solution and its ability to deliver actionable insightsand sustainable value for both retailers and brands.
“Hanshow’s Shelf Marketing Solution stood out for its creativity, technical excellence, and clear commercial results,” said Scott Thompson, Founder and Editor of RTIH. “By transforming Electronic Shelf Labels into a bridge between physical stores and digital engagement, Hanshow demonstrates how innovation can deliver measurable value for both retailers and consumers. We are delighted to recognise Hanshow as our Technology Vendor of the Year.”
“This recognition marks another milestone for Hanshow in our global Retail Media Network strategy,” said Liangyan Li, SVP and Head of Global Sales at Hanshow. “By transforming electronic shelf labels into digital marketing gateways, we’re helping retailers and brands unlock measurable in-store media value and create a more connected, data-driven customer experience.”
The Tap-to-Collect NFC ESL Coupons initiative exemplifies Hanshow’s innovative spirit—repurposing existing infrastructure to empower data-driven retail and performance-based marketing. This achievement further cements Hanshow’s leadership in connected retail, retail media transformation, and personalised digital engagement, advancing the company’s mission to shape the next generation of intelligent retail experiences worldwide.
According to the RTIH, the Innovation Awards “celebrate global tech innovation in a fast-moving omnichannel world,” spotlighting how retailers and vendors are using technology to create real business and consumer impact. For Hanshow, this recognition marks not only an industry honour but also a validation of its long-term strategy to integrate intelligence, connectivity, and sustainability into every aspect of retail.
View source version on businesswire.com: https://www.businesswire.com/news/home/20251023122859/en/
Contacts
Info@hanshow.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
www.businesswire.com

Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 20:52:00 EEST | Press release
International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he has served as pro bono counsel to five Nobel Peace Prize laureates. The New York Times has referred to him as "The Extractor" for his work freeing political prisoners worldwide. Genser's decision to support Yim Leak's team comes as the businessman faces an asset freeze exceeding 20 billion baht (more than U
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 18:38:00 EEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli ® (Relacorilant)18.9.2026 15:00:00 EEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu ® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 15:00:00 EEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at the 2025 European Society for Medical Oncology (#ESMO25) Congress and subsequently published in The New England Journal of Medicine. The recommendation will now be reviewed by the European Commission, which has the authority to grant marketing authorizations for medicines in the EU. In DES
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca ® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 13:58:00 EEST | Press release
Alfasigma S.p.A, a global pharmaceutical company with a focus on innovation in rare disease and specialty care in areas where there is significant unmet patient need, today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for Jyseleca® (filgotinib), an oral, once-daily JAK1 preferential inhibitor, for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy. Following this positive opinion, the application is now referred to the European Commission (EC) for final action. The EC’s decision is expected in the next weeks. “At present, half of people living with axSpA fail to adequately respond to treatment, leaving them with years of preventable struggle with persistent pain and other impactful symptoms,” said Daniele D'Ambrosio, Chief Development Officer, Alfasigma. “This
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom